Table 1 Patient characteristics in ALL, HR-NB and EWS.

From: Whole-genome sequencing facilitates patient-specific quantitative PCR-based minimal residual disease monitoring in acute lymphoblastic leukaemia, neuroblastoma and Ewing sarcoma

Patient ID

Age (yr)

Gender

Diagnosis

Status of IG/TCR rearrangement (ALL), MYCN (HR-NB), EWSR1 fusion (EWS)

ALL-1

9.9

F

T-ALL

IGH: VH4-DH2-JH4

ALL-2

2.1

M

B-ALL

TCRB: DB1-JB1.5

ALL-3

4.6

F

B-ALL

TCRG: Vg3-Jg2

ALL-4

14.7

F

B-ALL

IGK: VK2-Kdel

ALL-5

9.1

F

B-ALL

TCRA: Vd2-Dd3-Ja29

ALL-6

7.1

M

T-ALL

TCRG: Vg11-Jg2

HR-NB1

4.2

F

HR-NB

MYCN not amplified

HR-NB2

0.8

M

HR-NB

MYCN amplified

HR-NB3

2

F

HR-NB

MYCN not amplified

HR-NB4

5

M

HR-NB

MYCN not amplified

HR-NB5

7.5

M

HR-NB

MYCN not amplified

HR-NB6

3

F

HR-NB

MYCN not amplified

EWS-1

8

M

EWS

EWSR1-FLI1

EWS-2

1.2

M

EWS

EWSR1-FLI1

EWS-3

12

M

EWS

EWSR1-FLI1

EWS-4

8.3

F

EWS

EWSR1-ETV1

EWS-5

15.9

M

EWS

EWSR1-ERG

EWS-6

3.3

M

EWS

EWSR1-ETV1

  1. ALL acute lymphoblastic leukaemia, HR-NB high-risk neuroblastoma, EWS Ewing sarcoma, B-ALL B acute lymphoblastic leukaemia, T-ALL T cell acute lymphoblastic leukaemia.